Pfizer Inc (PFE): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2.1%. By the end of trading, Pfizer rose $0.46 (1.5%) to $31.00 on average volume. Throughout the day, 32,898,508 shares of Pfizer exchanged hands as compared to its average daily volume of 24,899,500 shares. The stock ranged in a price between $30.55-$31.05 after having opened the day at $30.58 as compared to the previous trading day's close of $30.54. Other companies within the Drugs industry that increased today were: iBio ( IBIO), up 34.8%, MediciNova ( MNOV), up 32.1%, China Pharma ( CPHI), up 28.5% and Telik ( TELK), up 27.5%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $198.9 billion and is part of the health care sector. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7. Shares are down 0.3% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Rexahn Pharmaceuticals ( RNN), down 27.5%, Tonix Pharmaceuticals ( TNXP), down 10.8%, Galectin Therapeutics ( GALT), down 10.5% and Heat Biologics ( HTBX), down 8.5% , were all laggards within the drugs industry with Intercept Pharmaceuticals ( ICPT) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump